Literature DB >> 18822996

Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 1: study design.

Robert H Howland1.   

Abstract

This article describes the design of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. The main study objective was to compare the efficacy and tolerability of various antidepressant therapies through four sequential treatment levels. To maximize the generalizability of the results, broad inclusion and minimal exclusion criteria were used to recruit patients with major depression from a large number of real-world settings. The goal of treatment was to achieve full remission. A measurement-based care system was used to guide and optimize treatment at each level. Patients were treated for up to 12 weeks at each level (with an optional week 14 visit, if needed). All patients started with citalopram at Level 1. The three subsequent levels of treatment options were randomized and open label, and patients could accept or decline treatments as long as sufficient options were left that allowed randomization between at least two different options. For any treatment level, patients who reached full remission, and those with satisfactory response, could continue the same treatment during 1-year naturalistic follow up. Patients who did not reach full remission were encouraged to enter subsequent levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18822996     DOI: 10.3928/02793695-20080901-06

Source DB:  PubMed          Journal:  J Psychosoc Nurs Ment Health Serv        ISSN: 0279-3695            Impact factor:   1.098


  7 in total

1.  Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.

Authors:  Chiara Fabbri; Concetta Crisafulli; Raffaella Calati; Diego Albani; Gianluigi Forloni; Marco Calabrò; Rosalba Martines; Siegfried Kasper; Joseph Zohar; Alzbeta Juven-Wetzler; Daniel Souery; Stuart Montgomery; Julien Mendlewicz; Alessandro Serretti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-04       Impact factor: 5.270

2.  Physiologically relevant changes in serotonin resolved by fast microdialysis.

Authors:  Hongyan Yang; Andrew B Thompson; Bryan J McIntosh; Stefanie C Altieri; Anne M Andrews
Journal:  ACS Chem Neurosci       Date:  2013-04-24       Impact factor: 4.418

3.  Neuronal cell adhesion genes and antidepressant response in three independent samples.

Authors:  C Fabbri; C Crisafulli; D Gurwitz; J Stingl; R Calati; D Albani; G Forloni; M Calabrò; R Martines; S Kasper; J Zohar; A Juven-Wetzler; D Souery; S Montgomery; J Mendlewicz; G D Girolamo; A Serretti
Journal:  Pharmacogenomics J       Date:  2015-04-07       Impact factor: 3.550

4.  Polygenic risk scores for neuropsychiatric, inflammatory, and cardio-metabolic traits highlight possible genetic overlap with suicide attempt and treatment-emergent suicidal ideation.

Authors:  Giuseppe Fanelli; Marcus Sokolowski; Danuta Wasserman; Siegfried Kasper; Joseph Zohar; Daniel Souery; Stuart Montgomery; Diego Albani; Gianluigi Forloni; Panagiotis Ferentinos; Dan Rujescu; Julien Mendlewicz; Diana De Ronchi; Alessandro Serretti; Chiara Fabbri
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2022-02-21       Impact factor: 3.358

5.  Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway.

Authors:  Enrico Cocchi; Chiara Fabbri; Changsu Han; Soo-Jung Lee; Ashwin A Patkar; Prakash S Masand; Chi-Un Pae; Alessandro Serretti
Journal:  BMC Psychiatry       Date:  2016-04-18       Impact factor: 3.630

6.  Evaluation of QTc prolongation and dosage effect with citalopram.

Authors:  Justine McClelland; Monica Mathys
Journal:  Ment Health Clin       Date:  2016-06-29

Review 7.  Lateral Habenula Gone Awry in Depression: Bridging Cellular Adaptations With Therapeutics.

Authors:  Alvaro Nuno-Perez; Anna Tchenio; Manuel Mameli; Salvatore Lecca
Journal:  Front Neurosci       Date:  2018-07-23       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.